Pregabalin Capsule
Product Images NDC 71335-1791

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1791). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351791)

Pregabalin Capsules USP 25 mg oral dosage form label by Bryant Ranch Prepack. The label includes dosage strength prominently in a red-bordered box, an NDC number 63629-8199-01, and a package count of 30 capsules. It also displays the BRP Pharmaceuticals logo and storage instructions.*

FDA Label Image

Label (Lbl7133517912)

Pregabalin 25 mg (CV) Capsule label from Bryant Ranch Prepack. The label states the product is comparable to Lyrica 25 mg (CV) Capsule by Hetero Labs Limited. It includes storage instructions at 20°-25°C (68°-77°F), a warning to keep drugs out of reach of children, and the NDC 71335-1791. The label also shows a lot number, expiration date placeholder, and a barcode.*

FDA Label Image

Logo (Logo)

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for different dosages of Pregabalin (25 mg, 100 mg, 200 mg three times a day) compared to placebo. The x-axis represents percent improvement in pain, and the y-axis shows percent of patients improved, illustrating dose-dependent efficacy trends.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve graph comparing estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The y-axis shows the estimated percentage without LTR from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group maintains a higher percentage without LTR compared to placebo over time.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved from baseline to week 12 BOCF for Pregabalin and placebo. The x-axis shows percent improvement from 0 to 100, and the y-axis represents the percent of subjects improved from 0 to 100. Two curves are plotted: one solid line for Pregabalin and one dashed line for placebo, indicating a higher percentage of subjects improved with Pregabalin compared to placebo across various improvement levels.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing the percent of subjects improved over time from baseline to week 16 for Pregabalin versus placebo. The x-axis represents the percent improved from baseline to week 16, ranging from 0 to 100, while the y-axis shows the percent of subjects improved, ranging from 0 to 100. Two lines depict the progression: one solid line for Pregabalin and one dotted line for placebo.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line chart comparing percent of patients improved versus percent improvement in pain from baseline. The chart shows data for Pregabalin 100 mg three times a day and placebo, with two vertical lines marking specific percentages on the X-axis.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg doses taken two times a day, versus placebo. The chart shows higher patient improvement percentages with increasing Pregabalin doses compared to placebo.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows three lines indicating different treatment groups and their relative pain improvement distribution.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph comparing the percent of patients improved in pain from baseline versus the percent improvement in pain. It shows three curves representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating variations in pain improvement among these groups.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing response rates (%) across different dosing regimens of Pregabalin versus placebo in two studies labeled E1 and E3. The x-axis shows dosing groups including placebo, 600 mg/day, and other doses with varying frequency. The y-axis represents response rate percentage, illustrating dose-dependent increases in response rate in both studies.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph showing median percent reduction in seizures from baseline on the y-axis versus pregabalin dose in mg/day on the x-axis. Four studies are represented with different symbols and dosing schedules, illustrating dose-dependent seizure reduction and associated p-values indicating statistical significance.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph showing percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares four curves representing Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo, with higher doses showing slightly higher improvement percentages.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of pregabalin, depicting its molecular arrangement including amine, methyl groups, and carboxylic acid functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.